Patients with HIV are at risk of both primary and secondary haematological disorders. We report two cases of patients with HIV and cryptococcal meningitis who developed severe haemolytic anaemia, thrombocytopenia, renal failure and lactic acidosis while on treatment with amphotericin B and co-trimoxazole.
SaifMW. HIV-associated autoimmune hemolytic anemia: an update. AIDS Patient Care STDS2001; 15: 217–224.
2.
HsiehSMHungCCChenMY, et al.Efficacy and adverse effects of higher dose amphotericin B monotherapy for cryptococcal meningitis in patients with advanced HIV infection. Microbiol Immunol Infect1998; 31: 233–239.
3.
ReinkeCMThomasJKGravesAH. Apparent hemolysis in an AIDS patient receiving trimethoprim/sulfamethoxazole: case report and literature review. J Pharm Technol1996; 11: 256–262.
4.
PassosAMTreitingerASpadaC. An overview of the mechanisms of HIV-related thrombocytopenia. Acta Haematol2010; 124: 13–18.
5.
SalamaABurgerMMueller-EckhardtC. Acute immune hemolysis induced by a degradation product of amphotericin B. Blut1989; 58: 59–61.
6.
ArndtPAGarrattyGWolfCF, et al.Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and sulfamethoxazole. Transfus Med2011; 21: 194–198.
7.
ArnoldDMNaziIWarkentinTE, et al.Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev2013; 27: 137–145.
8.
YamreudeewongWFosnochtBJWeixelmanJM. Severe thrombocytopenia possibly associated with TMP/SMX therapy. Ann Pharmacother2002; 36: 78–82.
9.
FraserTNAvellanedaAAGravissEA, et al.Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother2012; 67: 1271–1277.
10.
SawayaBPBriggsJPSchnermannJ. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol1995; 6: 154–164.
11.
SutorGCSchmidtREAlbrechtH. Thrombotic microangiopathies and HIV infection: report of two typical cases, features of HUS and TTP, and review of the literature. Infection1999; 27: 12–15.
